Fatima Mohammed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatima Mohammed has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aanchal Mathur
Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain
1 shared publication - Anfal Jassim
Department of Molecular Medicine, College of Medicine and Medical Sciences, Al-Jawhara Center, Arabian Gulf University, Manama P.O. Box 26671, Bahrain
1 shared publication - Fatemah Bahman
Department of Immunology & Microbiology, Dasman Diabetes Institute, Dasman 15462, Kuwait
1 shared publication - Fiza Rashid-Doubell
School of Medicine, Royal College of Surgeons in Ireland–Medical University Bahrain, PO Box 15503, Busaiteen, Kingdom of Bahrain
1 shared publication - Ibrahim Mustafa El-Deeb
Institute for Biomedicine and Glycomics, Griffith University
1 shared publication - Khaled Greish
Department of Molecular Medicine & Nanomedicine Unit, Al Jawhara Centre for Molecular Medicine, Genetics & Inherited Diseases, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Bahrain
1 shared publication
Latest Publications
- Open Access
- 1 November 2018
- Published by MDPI AG in Nanomaterials
- Vol. 8 (11) , 884
Curcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer
Breast cancer is the most common cancer diagnosed among females worldwide. Although breast cancer survival has largely improved in the past 30 years, it remains highly heterogeneous in its response to treatment. Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor-2 (Her2). While TNBC may initially be responsive to chemotherapy, recurrence and subsequent high mortality rates are frequently reported. Studies have shown curcumin and its derivatives to be effective against TNBC cell lines in vitro. To improve its anti-cancer effects, we have synthesized Fe3+–curcumin (Fe–Cur3) and Cu2+–curcumin (CD) complexes and investigated them experimentally. Further, CD was encapsulated into a poly(styrene)-co-maleic acid (SMA) micelle to enhance its stability. We assessed the cytotoxicity of these formulations both in vitro and in vivo. SMA–CD demonstrated dose-dependent cytotoxicity and abolished TNBC tumor growth in vivo. The encapsulation of the curcumin–copper complex improved its anti-cancer activity without overt adverse effects in a murine model of TNBC. These results provide evidence and insights into the value of nanoformulations in enhancing drug-delivery and increasing the potential therapeutic efficacy of curcumin derivatives.
- 1 November 2018
- Published by MDPI AG in Nanomaterials
- Vol. 8 (11) , 884
Open AccessCurcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer
Breast cancer is the most common cancer diagnosed among females worldwide. Although breast cancer survival has largely improved in the past 30 years, it remains highly heterogeneous in its response to treatment. Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor-2 (Her2). While TNBC may initially be responsive to chemotherapy, recurrence and subsequent high mortality rates are frequently reported. Studies have shown curcumin and its derivatives to be effective against TNBC cell lines in vitro. To improve its anti-cancer effects, we have synthesized Fe3+–curcumin (Fe–Cur3) and Cu2+–curcumin (CD) complexes and investigated them experimentally. Further, CD was encapsulated into a poly(styrene)-co-maleic acid (SMA) micelle to enhance its stability. We assessed the cytotoxicity of these formulations both in vitro and in vivo. SMA–CD demonstrated dose-dependent cytotoxicity and abolished TNBC tumor growth in vivo. The encapsulation of the curcumin–copper complex improved its anti-cancer activity without overt adverse effects in a murine model of TNBC. These results provide evidence and insights into the value of nanoformulations in enhancing drug-delivery and increasing the potential therapeutic efficacy of curcumin derivatives.